Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope against Drug-Resistant yeast infections?

NCT ID NCT03604705

Completed Disease control Sponsor: Basilea Pharmaceutica Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested an experimental drug called APX001 in 21 adults with Candida bloodstream infections, including cases where standard antifungals might not work. Participants received the drug for up to 14 days, with possible follow-up treatment. The goal was to see if the drug could clear the infection and improve survival. Results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
APX001 (an experimental antifungal drug)
What this could lead to
If successful, this could point toward a new treatment option for serious Candida bloodstream infections, especially those resistant to current antifungals.
What could go wrong
This is a very small, early-phase trial with only 21 participants and no comparison group. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANDIDEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

candidemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANDIDEMIA

Contacts and locations

Locations

  • Augusta University (Georgia Regents University)

    Augusta, Georgia, 30901, United States

  • CHU de Charleroi - Hopital Civil Marie Curie

    Lodelinsart, Belgium

  • Duke University Hospital Medical Center

    Durham, North Carolina, 27710, United States

  • Hopital Erasme

    Brussels, 1070, Belgium

  • Hospital General Universitario de Alicante

    Alicante, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario Mutua de Terrassa

    Terrassa, Barcelona, Spain

  • Hospital VLL D Hebron

    Barcelona, Spain

  • Infectious Diseases Unit

    Tel Aviv, 6423906, Israel

  • Infectious Diseases Unit, Rambam Medical Center

    Haifa, 3109601, Israel

  • Infectious Diseases Unit,Sheba Medical Center

    Tel Litwinsky, 52621, Israel

  • Institut Jules Bordet

    Brussels, Belgium

  • Institut Jules Bordet,Service De Microbiologie

    Brussels, 1000, Belgium

  • Klinik I fur Innere Medizin- Uniklinik Koln

    Cologne, Germany

  • Mont-Godinne University Hospital

    Yvoir, 5530, Belgium

  • Rambam Medical Center

    Haifa, Israel

  • Sheba Medical Center

    Tel Litwinsky, Israel

  • Sourasky Medical Center

    Tel Aviv, Israel

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - III. Medizinische Klinik Haematologie/Onkologie

    Mainz, Germany

  • Universite Libre de Bruxelles (ULB) - Hopital Erasme

    Brussels, Belgium

  • University Hospital Heidelberg

    Heidelberg, Germany

  • University Hospital Mont-Godinne

    Yvoir, Belgium

  • University of Alabama at Birmingham (UAB)

    Birmingham, Alabama, 35249, United States

  • University of Alabama at Birmingham School of Medicine

    Birmingham, Alabama, 35233, United States

  • University of California, Davis

    Davis, California, 95616, United States

  • University of California-Davis Medical Center

    Sacramento, California, 95817, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • University of Texas- Health Science Center and Medical School at Houston

    Houston, Texas, 77030, United States

  • Washington University

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.